<DOC>
	<DOCNO>NCT00038792</DOCNO>
	<brief_summary>Phase II efficacy evaluation , phase I/II efficacy toxicity trial recombinant human keratinocyte growth factor treatment steroid refractory gastrointestinal graft versus host disease .</brief_summary>
	<brief_title>Phase I/II Trial rHuKFG Treatment Steroid Refractory Gastrointestinal Acute GVHD</brief_title>
	<detailed_description>There two process cause diarrhea clinical manifestation graft versus host disease . The first obvious immunologic attack colonic epithelium recipient . Once immunologic attack abate recipient leave colonic mucosa devoid microvilli smooth intestinal boarder . This frequently subject superinfection bacteria cause diarrhea continue . Researchers endpoint measure clinical response immunosuppression resolution diarrhea . The human recombinant keratinocyte growth factor stimulate growth colonic epithelium . The growth colonic epithelium turn probably ameliorate diarrhea associate graft versus host disease .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion criterion : Patients post allogeneic bone marrow transplant watery diarrhea progress 2mg/kg steroid 3 day fail improve 5 day . Patients may skin liver involvement graft versus host disease . Patients infection etiology diarrhea . Exclusion criterion :</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Acute Graft Versus Host Disease</keyword>
	<keyword>Refractory</keyword>
</DOC>